LT2885266T - (2z,5z)-5-(3-chlor-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ono gamybos būdas ir šiame procese naudojamas tarpinis junginys - Google Patents
(2z,5z)-5-(3-chlor-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ono gamybos būdas ir šiame procese naudojamas tarpinis junginysInfo
- Publication number
- LT2885266T LT2885266T LTEP13779378.2T LT13779378T LT2885266T LT 2885266 T LT2885266 T LT 2885266T LT 13779378 T LT13779378 T LT 13779378T LT 2885266 T LT2885266 T LT 2885266T
- Authority
- LT
- Lithuania
- Prior art keywords
- propylimino
- dihydroxypropoxy
- thiazolidin
- benzylidene
- tolyl
- Prior art date
Links
- LPAUOXUZGSBGDU-ULCCENQXSA-N (5z)-5-[[3-chloro-4-[(2r)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=NCCC)S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-ULCCENQXSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/77—Preparation of chelates of aldehydes or ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/81—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12180920 | 2012-08-17 | ||
| PCT/IB2013/056662 WO2014027330A1 (en) | 2012-08-17 | 2013-08-15 | Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2885266T true LT2885266T (lt) | 2020-07-10 |
Family
ID=46940231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP13779378.2T LT2885266T (lt) | 2012-08-17 | 2013-08-15 | (2z,5z)-5-(3-chlor-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ono gamybos būdas ir šiame procese naudojamas tarpinis junginys |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9340518B2 (lt) |
| EP (1) | EP2885266B1 (lt) |
| JP (2) | JP6322630B2 (lt) |
| KR (1) | KR101731739B1 (lt) |
| CN (1) | CN104540800B (lt) |
| CA (1) | CA2895172C (lt) |
| CY (1) | CY1123300T1 (lt) |
| DK (1) | DK2885266T3 (lt) |
| ES (1) | ES2795105T3 (lt) |
| HR (1) | HRP20200883T1 (lt) |
| HU (1) | HUE050733T2 (lt) |
| IL (1) | IL237198A (lt) |
| LT (1) | LT2885266T (lt) |
| MX (1) | MX350891B (lt) |
| PL (1) | PL2885266T3 (lt) |
| PT (1) | PT2885266T (lt) |
| RS (1) | RS60408B1 (lt) |
| SI (1) | SI2885266T1 (lt) |
| SM (1) | SMT202000298T1 (lt) |
| TW (1) | TWI606036B (lt) |
| WO (1) | WO2014027330A1 (lt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 |
| SI2885266T1 (sl) * | 2012-08-17 | 2020-10-30 | Actelion Pharmaceuticals Ltd | Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina |
| WO2016091996A1 (en) | 2014-12-11 | 2016-06-16 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| JP6691218B2 (ja) * | 2015-12-25 | 2020-04-28 | クリスタル ファーマテック カンパニー、リミテッドＣｒｙｓｔａｌ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．， Ｌｔｄ． | 選択的なｓ１ｐ１受容体アゴニストの新規な結晶形及びその製造方法 |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| WO2019060147A1 (en) * | 2017-09-19 | 2019-03-28 | Teva Pharmaceuticals Usa, Inc. | NEW CRYSTALLINE POLYMORPHE FROM PONESIMOD |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| KR102365655B1 (ko) | 2018-11-29 | 2022-02-22 | 원광대학교 산학협력단 | 콩 발효 추출물을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 조성물 |
| PH12022551043A1 (en) | 2019-10-31 | 2023-05-03 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| US20240368094A1 (en) | 2021-08-17 | 2024-11-07 | Teva Czech Industries S.R.O | Polymorphs of ponesimod |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2023152691A1 (en) * | 2022-02-10 | 2023-08-17 | Metrochem Api Pvt Ltd | Process for the preparation of ponesimod and its intermediates thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3077402A (en) | 1954-12-06 | 1963-02-12 | Polaroid Corp | Photographic color processes, products, and compositions |
| NL270002A (lt) | 1960-10-08 | |||
| GB1001479A (en) | 1962-10-10 | 1965-08-18 | Angeli Inst Spa | Glycerol ethers |
| OA03835A (fr) | 1970-07-17 | 1971-12-24 | Rhone Poulenc Sa | Nouveaux dérivés de la thiazolidine, leur préparation et les compositions qui les contiennent. |
| PT97507B (pt) | 1990-04-27 | 1998-08-31 | Orion Yhtymae Oy | Processo para apreparacao de novos derivados de catecol farmacologicamente activos |
| TW221689B (lt) | 1991-08-27 | 1994-03-11 | Otsuka Pharma Co Ltd | |
| US5677322A (en) | 1993-02-26 | 1997-10-14 | Otsuka Pharmaceutical Co., Ltd. | Maillard reaction inhibitor |
| KR960022486A (ko) | 1994-12-29 | 1996-07-18 | 김준웅 | 신규 티아졸리딘-4-온 유도체 |
| US6353006B1 (en) | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| ATE393150T1 (de) | 1999-09-14 | 2008-05-15 | Shionogi & Co | 2-imino-1,3-thiazin-derivate |
| US6380229B1 (en) | 1999-11-12 | 2002-04-30 | Fujimoto Co., Ltd. | 2-(N-cyanoimino)thiazolidin-4-one derivatives |
| US20050019825A9 (en) | 2002-03-15 | 2005-01-27 | Qing Dong | Common ligand mimics: pseudothiohydantoins |
| BR0312650A (pt) | 2002-07-10 | 2005-05-03 | Applied Research Systems | Derivados de benzeno fundido azolidinona-vinila |
| GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| US7183302B2 (en) | 2002-08-12 | 2007-02-27 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of HCV replication |
| ES2315566T3 (es) | 2002-11-22 | 2009-04-01 | Smithkline Beecham Corporation | Tiazolidin-4-onas para inhibir proteinas hyak3. |
| US20040167192A1 (en) | 2003-01-16 | 2004-08-26 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| WO2005037424A1 (en) | 2003-10-06 | 2005-04-28 | Solvias Ag | Process for the parallel detection of crystalline forms of molecular solids |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| EP2295418A1 (en) | 2003-11-21 | 2011-03-16 | Actelion Pharmaceuticals Ltd. | 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents |
| JP2007523957A (ja) | 2004-02-25 | 2007-08-23 | スミスクライン・ビーチャム・コーポレイション | 新規化学化合物 |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| KR20130041385A (ko) | 2004-11-29 | 2013-04-24 | 노파르티스 아게 | Ｓ１ｐ 수용체 효능제의 투여 용법 |
| WO2006094233A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N,n'-dicyclic isothiourea sirtuin modulators |
| US7846964B2 (en) | 2005-03-23 | 2010-12-07 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives as spingosine-1-phosphate-1 receptor agonists |
| EP1863787B1 (en) | 2005-03-23 | 2011-05-25 | Actelion Pharmaceuticals Ltd. | Hydogrenated benzo[c]thiophene derivatives as immunomodulators |
| CN101146529B (zh) | 2005-03-23 | 2012-08-29 | 埃科特莱茵药品有限公司 | 新颖噻吩衍生物作为鞘氨醇-1-磷酸酯-1受体激动剂 |
| CA2612661A1 (en) | 2005-06-24 | 2006-12-28 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
| AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| JP5063615B2 (ja) | 2006-01-24 | 2012-10-31 | アクテリオン ファーマシューティカルズ リミテッド | 新規ピリジン誘導体 |
| US7879821B2 (en) | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| MY149853A (en) | 2006-09-07 | 2013-10-31 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
| CL2007002594A1 (es) | 2006-09-08 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. . |
| KR20090051774A (ko) | 2006-09-21 | 2009-05-22 | 액테리온 파마슈티칼 리미티드 | 페닐 유도체 및 면역조절제로서 이들의 용도 |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| DK2094676T3 (da) * | 2006-11-23 | 2013-06-10 | Actelion Pharmaceuticals Ltd | Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater |
| DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| KR101541558B1 (ko) | 2007-08-17 | 2015-08-03 | 액테리온 파마슈티칼 리미티드 | Ｓ1ｐ1/ｅｄｇ1 수용체 조절제로서의 피리딘 유도체 |
| KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 |
| GB0819182D0 (en) * | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| US20100160369A1 (en) * | 2008-12-04 | 2010-06-24 | Exelixis, Inc. | S1P1 Agonists and Methods of Making And Using |
| HRP20151190T1 (hr) | 2008-12-22 | 2016-01-01 | Novartis Ag | Režim doziranja za fingolimod u lijeäśenju multiple skleroze |
| JP5657565B2 (ja) | 2008-12-22 | 2015-01-21 | ノバルティス アーゲー | Ｓ１ｐ受容体アゴニストの投与レジメン |
| SI2885266T1 (sl) * | 2012-08-17 | 2020-10-30 | Actelion Pharmaceuticals Ltd | Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina |
-
2013
- 2013-08-15 SI SI201331742T patent/SI2885266T1/sl unknown
- 2013-08-15 SM SM20200298T patent/SMT202000298T1/it unknown
- 2013-08-15 ES ES13779378T patent/ES2795105T3/es active Active
- 2013-08-15 LT LTEP13779378.2T patent/LT2885266T/lt unknown
- 2013-08-15 PL PL13779378T patent/PL2885266T3/pl unknown
- 2013-08-15 RS RS20200642A patent/RS60408B1/sr unknown
- 2013-08-15 WO PCT/IB2013/056662 patent/WO2014027330A1/en not_active Ceased
- 2013-08-15 MX MX2015002127A patent/MX350891B/es active IP Right Grant
- 2013-08-15 PT PT137793782T patent/PT2885266T/pt unknown
- 2013-08-15 JP JP2015527061A patent/JP6322630B2/ja active Active
- 2013-08-15 HR HRP20200883TT patent/HRP20200883T1/hr unknown
- 2013-08-15 DK DK13779378.2T patent/DK2885266T3/da active
- 2013-08-15 CN CN201380042658.2A patent/CN104540800B/zh active Active
- 2013-08-15 HU HUE13779378A patent/HUE050733T2/hu unknown
- 2013-08-15 EP EP13779378.2A patent/EP2885266B1/en active Active
- 2013-08-15 KR KR1020157006474A patent/KR101731739B1/ko active Active
- 2013-08-15 CA CA2895172A patent/CA2895172C/en active Active
- 2013-08-15 US US14/422,167 patent/US9340518B2/en active Active
- 2013-08-16 TW TW102129570A patent/TWI606036B/zh not_active IP Right Cessation
-
2015
- 2015-02-12 IL IL237198A patent/IL237198A/en active IP Right Grant
-
2017
- 2017-04-13 JP JP2017079804A patent/JP6424250B2/ja active Active
-
2020
- 2020-06-11 CY CY20201100532T patent/CY1123300T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2885266A1 (en) | 2015-06-24 |
| CY1123300T1 (el) | 2021-12-31 |
| JP2017160223A (ja) | 2017-09-14 |
| SMT202000298T1 (it) | 2020-07-08 |
| KR20150042277A (ko) | 2015-04-20 |
| HUE050733T2 (hu) | 2021-01-28 |
| KR101731739B1 (ko) | 2017-05-11 |
| MX350891B (es) | 2017-09-22 |
| TW201408634A (zh) | 2014-03-01 |
| US20150203459A1 (en) | 2015-07-23 |
| US9340518B2 (en) | 2016-05-17 |
| JP2015530373A (ja) | 2015-10-15 |
| JP6424250B2 (ja) | 2018-11-14 |
| WO2014027330A1 (en) | 2014-02-20 |
| IL237198A (en) | 2017-12-31 |
| ES2795105T3 (es) | 2020-11-20 |
| CA2895172C (en) | 2020-08-18 |
| RS60408B1 (sr) | 2020-07-31 |
| CN104540800A (zh) | 2015-04-22 |
| PT2885266T (pt) | 2020-05-29 |
| TWI606036B (zh) | 2017-11-21 |
| CN104540800B (zh) | 2017-05-10 |
| MX2015002127A (es) | 2015-05-11 |
| CA2895172A1 (en) | 2014-02-20 |
| JP6322630B2 (ja) | 2018-05-09 |
| PL2885266T3 (pl) | 2020-11-16 |
| HRP20200883T1 (hr) | 2020-09-04 |
| EP2885266B1 (en) | 2020-03-18 |
| DK2885266T3 (da) | 2020-06-08 |
| IL237198A0 (en) | 2015-04-30 |
| SI2885266T1 (sl) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2885266T3 (pl) | Sposób otrzymywania (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroksypropoksy)benzylideno)-2-(propyloimino)-3-(o-tolilo)tiazolidyn-4-onu i produktu pośredniego stosowanego w tym sposobie | |
| IL281024A (en) | Pharmaceutical preparations containing N–(3,5–DIMETHOXYPHENYL)–N'–(1–METHYLETHYL)–N–[3–(1–METHYL–1H–PYRAZOL–4–YL)QUINOXALIN–6–YL]ETHANE–1, 2-DIAMINE | |
| IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
| IL245882B (en) | Process for the preparation of n-[(3-aminooxetane-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazepine-4-yl)-6-methyl-quinazoline- 4-Amin | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| PL3481846T3 (pl) | 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA | |
| EP3307738A4 (en) | ARYL-DIHYDRO-2H-BENZO [B] [1,4] OXAZINE-SULPHONAMIDE AND RELATED COMPOUNDS FOR USE AS AGENTS OF RORY AND FOR THE TREATMENT OF DISEASES | |
| EP3292119A4 (en) | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | |
| BR112013022523A2 (pt) | uso de glicopirrolato para o tratamento de taquicardia | |
| IL288194A (en) | A compound for use in the treatment of neurogenic standing hypotension | |
| BR112013006857A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica e método para o tratamento ou profilaxia de doenças virais | |
| BR112015001169A2 (pt) | polimorfo, uso do polimorfo, composição farmacêutica e uso para preparar o polimorfo | |
| PL3655395T3 (pl) | Proces otrzymywania n-((1r,2s,sr)-5-(tert-butyloamino)-2-((s)-3-(7-tert-butylopirazolo[1,5-a][1,3,5]triazyn-4-yloamino)-2-oksopirolidyn-1-ylo)cykloheksylo)acetamidu | |
| HK1242618A1 (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| ZA201603729B (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| PT3256109T (pt) | Composições farmacêuticas compreendendo n-(3,5-dimetoxifenil)-n¿-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina | |
| PL3436009T3 (pl) | Ujemne modulatory allosteryczne mglur5 do użycia w leczeniu rozwiniętych uszkodzeń mózgu | |
| PL396491A1 (pl) | Chlorowodorek N-benzoilo-N-1-[(2R,S)-fenylopropylo]piperazyny i sposób jego wytwarzania |